sRAGE Linked to Risk of Incident Diabetic Nephropathy

Share this content:
sRAGE Linked to Risk of Incident Diabetic Nephropathy
sRAGE Linked to Risk of Incident Diabetic Nephropathy

THURSDAY, June 22, 2017 (HealthDay News) -- Serum levels of soluble receptor for advanced glycation end products (sRAGE) are associated with the risk of developing incident diabetic nephropathy (DN) in individuals with type 1 diabetes, according to a study published online June 19 in Diabetes Care.

Ronald Klein, M.D., from the University of Wisconsin School of Medicine and Public Health in Madison, and colleagues examined the correlation between serum levels of carboxymethyl lysine (CML) and sRAGE and the risk of developing incident DN over a 22-year period. Relevant data were included for 676 participants who contributed 2,350 person-intervals to the Multistate Markov models.

The researchers found that the estimated five-year incidence of DN was 15 percent. Higher levels of sRAGE were significantly associated with incidence of DN after adjustment for duration of diabetes (hazard ratio, 1.12 per 0.2 log pg/mL). After further adjustment for age at diagnosis of diabetes and hemoglobin A1c level, the significant correlation persisted, as did the correlations for sRAGE with incidence of chronic kidney disease (CKD) and proteinuria. There was no significant association for CML level with development of DN, CKD, or proteinuria. Higher levels of sRAGE and CML correlated with increased risk of death following DN (hazard ratios, 1.12 and 1.08 per 0.2 log pg/mL, respectively), after adjustment for other factors.

"We found evidence that serum levels of sRAGE are modestly but significantly associated with the incidence of DN independent of other risk factors studied," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »